In a filing, Aurinia Pharmaceuticals Inc revealed its Chief Commercial Officer Habig Scott Michael unloaded Company’s shares for reported $96902.0 on Aug 06 ’24. In the deal valued at $5.31 per share,18,249 shares were sold. As a result of this transaction, Habig Scott Michael now holds 456,338 shares worth roughly $3.42 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Balakrishnan Brinda sold 520 shares, generating $2,985 in total proceeds. Upon selling the shares at $5.74, the Director now owns 17,523 shares.
Before that, Billen Daniel sold 5,252 shares. Aurinia Pharmaceuticals Inc shares valued at $30,146 were divested by the Director at a price of $5.74 per share. As a result of the transaction, Billen Daniel now holds 28,141 shares, worth roughly $0.21 million.
Oppenheimer downgraded its Aurinia Pharmaceuticals Inc [AUPH] rating to a Perform from a an Outperform in a research note published recently. Oppenheimer also remained covering AUPH and has increased its forecast on December 10, 2021 with a “an Outperform” recommendation from previously “Perform” rating. Oppenheimer revised its rating on October 28, 2021. It rated AUPH as “a Perform” which previously was an “an Outperform”.
Price Performance Review of AUPH
On Tuesday, Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] saw its stock jump 3.45% to $7.49. Over the last five days, the stock has gained 5.94%. Aurinia Pharmaceuticals Inc shares have fallen nearly -16.69% since the year began. Nevertheless, the stocks have risen 4.17% over the past one year. While a 52-week high of $10.05 was reached on 01/10/24, a 52-week low of $4.71 was recorded on 04/18/24. SMA at 50 days reached $6.98, while 200 days put it at $6.07.
Levels Of Support And Resistance For AUPH Stock
The 24-hour chart illustrates a support level at 7.28, which if violated will result in even more drops to 7.07. On the upside, there is a resistance level at 7.60. A further resistance level may holdings at 7.71. The Relative Strength Index (RSI) on the 14-day chart is 64.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 1.16%. Stochastics %K at 82.09% indicates the stock is a selling.
How much short interest is there in Aurinia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Aurinia Pharmaceuticals Inc stocks on 2024-10-15, dropping by -0.39 million shares to a total of 7.19 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 7.58 million shares. There was a decline of -5.42%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 25, 2021 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $35.
